Sara M. Mangsbo

Uppsala University — Sweden

Immunology and Microbiology · Life Sciences

33h-index3.2kcitations162works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(70), Cancer Immunotherapy and Biomarkers(55), Bladder and Urothelial Cancer Treatments(51), Monoclonal and Polyclonal Antibodies Research(29), CAR-T cell therapy research(23)

Publications162 total

Optimizing T cell responses of targeted peptide antigen delivery by modulating antigen processing through amino acid exchange
International Journal of Biological Macromolecules·2026Open Access
Abstract 3448: Profiling the urinary bladder cancer composition and inter-cellular proximity patterns using single-cell RNA-sequencing and spatial transcriptomics
Cancer Research·2025
Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement
Molecular Therapy Oncology·2025· 1 citedOpen Access
Repeated positron emission tomography tracing neutrophil elastase in a porcine intensive-care sepsis model
Intensive Care Medicine Experimental·2025Open Access
Blood Levels of Dendritic Cell Populations in Patients with Moderate to Severe Traumatic Brain Injury
Neurotrauma Reports·2025Open Access
A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in mice
Nature Communications·2024· 7 citedOpen Access
Correction: Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations
PLoS ONE·2024· 1 citedOpen Access
Abstract CT108: Phase I data from TENDU101, a first-in-human trial of a novel synthetic peptide conjugate cancer vaccine platform assessed in recurrent prostate cancer patients before salvage treatment
Cancer Research·2024· 1 cited
MALT1 inhibition suppresses antigen-specific T cell responses
Cellular Immunology·2024· 2 citedOpen Access
Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model
International Immunopharmacology·2023· 4 citedOpen Access
Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
BMC Cancer·2023· 18 citedOpen Access
Epitopes Displayed in a Cyclic Peptide Scaffold Bind SARS‐COV‐2 Antibodies
ChemBioChem·2023· 3 citedOpen Access
Abstract 2929: Modular peptide cargo delivery by targeting CD40 enables ligandome driven, precision immunotherapy via the Adaptable Drug Affinity Conjugate (ADAC™) technology
Cancer Research·2023· 1 cited
Supplementary Table 2 from Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer
2023Open Access
Supplementary Table 1 from Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer
2023Open Access
Supplementary Table 1 from Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer
2023Open Access
Supplementary Figures 1 through 3 from The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
2023Open Access
Supplementary Figure 2 from Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer
2023Open Access
Supplementary Table 3 from Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer
2023Open Access
Supplementary Table 4 from Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Thomas H. Tötterman(15), Angelica Loskog(14), Sebastian Havervall(7), Mia Phillipson(7), Peter Nilsson(7), Sophia Hober(7), Charlotte Thålin(7), Peter Ellmark(7), Anna Dimberg(6), Nina Greilert‐Norin(6), Jonas Klingström(6), Luuk van Hooren(5), Henry Ng(5), Ulrika Marking(5), Martin Lord(5), Mikael Åberg(5), Linda C. Sandin(4), Erika Fletcher(4), Gustav Gaudernack(4), Lisa Christiansson(4)